amubarvimab (BRII-196) - Brii Biosci
Evusheld (cilgavimab/tixagevimab) - AstraZeneca
bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
romlusevimab (BRII-198) - Brii Biosci
Xevudy (sotrovimab) - GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
http://www.ncbi.nlm.nih.gov/pubmed/38815595
 
; Adam Rupert; Amy Weintrob; Anna L Goodman; Birgit Grund; Bradley G Leshnower; Charalampos D Moschopoulos; Daniel D Murray; David Looney; Eleftherios Mylonakis; Emily R Ko; Greg A Grandits; Helene C Highbarger; Henry Mugerwa; Jason V Baker; Jens Lundgren; Katherine Wick; Kathryn Shaw-Saliba; M Tauseef Rehman; Magdalena Ardelt; Mahsa Abassi; Mamta K Jain; Mark Holodniy; Michael A Matthay; Perrine Lallemand; Peter Chen; Randy Stevens; Robin L Dewar; Stephanie Nagy-Agren; Stuart Turville; Sylvain Laverdure; Thomas A Murray; Timothy J Hatlen; Tomas O Jensen
 
May 31, 2024
 
Prev Next